Neutropenia Biologic Drug Treatment Market Report 2026

The neutropenia biologic drug treatment market size has grown strongly in recent years. It will grow from $14.78 billion in 2025 to $15.79 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to growth in cancer chemotherapy usage, approval of filgrastim-based therapies, rising infection-related hospitalizations, adoption of supportive oncology care, hospital protocol standardization.

The neutropenia biologic drug treatment market size is expected to see strong growth in the next few years. It will grow to $20.88 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing oncology patient population, biosimilar penetration growth, demand for long-acting formulations, expansion of outpatient cancer care, rising healthcare expenditure. Major trends in the forecast period include increasing use of g-csf biologics, rising adoption of long-acting biologic therapies, growth in chemotherapy-induced neutropenia management, focus on biosimilars for cost reduction, expansion of hospital and oncology pharmacy distribution.

The increasing number of cancer cases worldwide is expected to support the growth of the neutropenia biologic drug treatment market. Rising cancer incidence, along with a growing number of patients undergoing chemotherapy, has led to a higher prevalence of neutropenia among cancer patients. For example, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, an estimated 165,000 Australians were newly diagnosed with cancer in 2023, representing more than 450 new cases each day, with males accounting for around 55% of these diagnoses. As a result, the global rise in cancer incidence is anticipated to increase demand for neutropenia biologic drug treatments in the coming years.

Leading companies operating in the neutropenia biologic drug treatment market are focusing on the development of biosimilars to provide more affordable alternatives to existing biologic therapies. Biosimilars are biologic medicines that are highly similar to already approved reference biologics, with no meaningful differences in safety or efficacy. For instance, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company, introduced Fylnetra (pegfilgrastim-pbbk), a biosimilar to Neulasta, for the prevention and treatment of febrile neutropenia in patients receiving chemotherapy. Fylnetra works by binding to specific receptors on hematopoietic cells, stimulating the growth and differentiation of neutrophil precursors in the bone marrow. This mechanism increases neutrophil production, which is essential for combating infections in patients undergoing myelosuppressive chemotherapy, thereby lowering the risk of chemotherapy-associated febrile neutropenia.

In April 2023, Assertio Holdings, Inc., a US-based specialty pharmaceutical company, acquired Spectrum Pharmaceuticals, Inc. for approximately $250 million. This acquisition is intended to strengthen Assertio’s oncology portfolio, support long-term revenue growth, enhance profitability, and expand its commercial reach across specialty therapeutics. Spectrum Pharmaceuticals, Inc. is a US-based biotechnology company specializing in the development and commercialization of innovative and targeted oncology treatments.

Major companies operating in the neutropenia biologic drug treatment market are Amgen Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Johnson & Johnson, Baxter International Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, Bayer AG, Sun Pharmaceutical Industries Ltd., Lupin Limited, Fresenius SE & Co. KGaA, Kyowa Kirin Co. Ltd., CSL Limited, Dr. Reddy's Laboratories Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd.

North America was the largest region in the neutropenia biologic drug treatment market in 2025. The regions covered in the neutropenia biologic drug treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neutropenia biologic drug treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the neutropenia biologic drug treatment market by increasing costs of biologic raw materials, sterile manufacturing equipment, and cold-chain transport systems. Long-acting biologics such as pegfilgrastim are more impacted due to higher production complexity. North america and europe face cost pressures because of biologics import dependence and regulatory requirements. However, tariffs are promoting local biologics production and biosimilar development. These shifts are improving treatment affordability and supply chain stability over time.

The neutropenia biologic drug treatment market research report is one of a series of new reports that provides neutropenia biologic drug treatment market statistics, including neutropenia biologic drug treatment industry global market size, regional shares, competitors with a neutropenia biologic drug treatment market share, detailed neutropenia biologic drug treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neutropenia biologic drug treatment industry. This neutropenia biologic drug treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neutropenia biologic drug treatment refers to medications used to lower the risk of fever or infection while stimulating the bone marrow to increase neutrophil production. Neutropenia occurs due to a deficiency of neutrophils, a specific type of white blood cell.

The primary drugs used in neutropenia biologic drug treatment include filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, and sargramostim. Filgrastim is a recombinant form of granulocyte colony-stimulating factor that is administered by injection to enhance neutrophil production following chemotherapy. The various treatment types include antibiotic agents, granulocyte colony-stimulating factor (G-CSF), antifungal medications, and others, and these therapies are distributed through channels such as retail pharmacies, hospital pharmacies, and online pharmacies.

The neutropenia biologic drug treatment market consists of sales of cefepime, ceftazidime, piperacillin-tazobactam, and meropenem. Values in this market are 'factory gate values', that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.